{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enhanced+Label",
    "query": {
      "intervention": "Enhanced Label"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 231,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enhanced+Label&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T10:57:41.584Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05854212",
      "title": "Behavioral Economics to Implement Nutrition Ranking in Food Pantries",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Food Insecurity",
        "Dietary Quality",
        "Behavioral Economics",
        "Implementation Science"
      ],
      "interventions": [
        {
          "name": "Behavioral economics-enhanced user interface",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 364,
      "start_date": "2027-01-01",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-09-12T10:57:41.584Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05854212"
    },
    {
      "nct_id": "NCT06748872",
      "title": "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Gastro-esophageal Junction Cancer",
        "Soft Tissue Sarcoma (STS)",
        "Myxoid Liposarcoma",
        "Synovial Sarcoma"
      ],
      "interventions": [
        {
          "name": "Lymphodepletion",
          "type": "DRUG"
        },
        {
          "name": "TCR-T cells (MDG1015)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Medigene AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2025-07-01",
      "completion_date": "2042-08-01",
      "has_results": false,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-09-12T10:57:41.584Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06748872"
    },
    {
      "nct_id": "NCT05324501",
      "title": "A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "MTX110",
          "type": "DRUG"
        },
        {
          "name": "Programmable pump and catheter system",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Biodexa Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2022-10-19",
      "completion_date": "2024-09-10",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-09-12T10:57:41.584Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida • Durham, North Carolina",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05324501"
    },
    {
      "nct_id": "NCT00669851",
      "title": "Acquiring Consensus for Contrast Echocardiography System Settings - ACCESS Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "AI-700",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acusphere",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 39,
      "start_date": "2006-11",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2008-05-01",
      "last_synced_at": "2026-09-12T10:57:41.584Z",
      "location_count": 1,
      "location_summary": "Watertown, Massachusetts",
      "locations": [
        {
          "city": "Watertown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00669851"
    },
    {
      "nct_id": "NCT05877716",
      "title": "EPI-MINN: Targeting Cognition and Motivation - National",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Psychosis",
        "Psychosis Nos/Other",
        "Schizophrenia",
        "Schizo Affective Disorder",
        "Schizoaffective Disorder",
        "Prodromal Schizophrenia",
        "Schizophrenia Spectrum and Other Psychotic Disorders",
        "Schizophreniform Disorders",
        "Major Depression With Psychotic Features",
        "Unspecified Psychosis",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Cognitive and Social Cognitive Training",
          "type": "DEVICE"
        },
        {
          "name": "Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Early Psychosis Coordinated Specialty Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "15 Years to 40 Years"
      },
      "enrollment_count": 55,
      "start_date": "2023-05-30",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-12T10:57:41.584Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05877716"
    },
    {
      "nct_id": "NCT05374525",
      "title": "A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "APRETUDE",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir OLI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 287,
      "start_date": "2022-05-18",
      "completion_date": "2024-08-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-09-12T10:57:41.584Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05374525"
    },
    {
      "nct_id": "NCT01893190",
      "title": "Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ruptured Cerebral Aneurysm",
        "Ruptured Berry Aneurysm"
      ],
      "interventions": [
        {
          "name": "Nimodipine",
          "type": "DRUG"
        },
        {
          "name": "Nimodipine Microparticles",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edge Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 73,
      "start_date": "2013-09",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2018-02-05",
      "last_synced_at": "2026-09-12T10:57:41.584Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01893190"
    },
    {
      "nct_id": "NCT04251117",
      "title": "GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HCC"
      ],
      "interventions": [
        {
          "name": "GNOS-PV02",
          "type": "BIOLOGICAL"
        },
        {
          "name": "INO-9012",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA®2000 EP Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Geneos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2020-03-01",
      "completion_date": "2028-11-29",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-09-12T10:57:41.584Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04251117"
    },
    {
      "nct_id": "NCT01778946",
      "title": "Nicotine Treatment of Cognitive Decline in Down Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Down Syndrome",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Low Dose Nicotine (7mg)",
          "type": "DRUG"
        },
        {
          "name": "Moderate Dose Nicotine (14mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2013-04",
      "completion_date": "2021-02",
      "has_results": true,
      "last_update_posted_date": "2022-05-10",
      "last_synced_at": "2026-09-12T10:57:41.584Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01778946"
    },
    {
      "nct_id": "NCT02544880",
      "title": "PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Tadalafil",
          "type": "DRUG"
        },
        {
          "name": "Anti-MUC1 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anti-Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tadalafil Placebo",
          "type": "OTHER"
        },
        {
          "name": "Anti-MUC1 Vaccine Placebo",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care Treatment",
          "type": "OTHER"
        },
        {
          "name": "Anti-Influenza Vaccine Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Donald T. Weed, MD, FACS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2016-04-25",
      "completion_date": "2021-06-08",
      "has_results": false,
      "last_update_posted_date": "2021-06-15",
      "last_synced_at": "2026-09-12T10:57:41.584Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02544880"
    }
  ]
}